AngioDynamics Announces Appointment of Former Johnson & Johnson Executive Karen Licitra to its Board of Directors
01 August 2019 - 6:01AM
Business Wire
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of
innovative, minimally invasive medical devices for vascular access,
peripheral vascular disease, and oncology, today announced the
appointment of Karen Licitra to its board of directors as a Class
III director, effective July 17, 2019.
“We are eager to work with Ms. Licitra and believe that her
extensive medical device, policy, and leadership experience will be
invaluable to us as we execute our strategy and become a leaner,
more innovation-focused company,” said Jim Clemmer, President and
Chief Executive Officer of AngioDynamics, Inc. “Attracting top
talent is a key component of our growth strategy, and we look
forward to Ms. Licitra’s contributions as an outstanding addition
to our board.”
“I’m honored to join the board and share my experience with the
dynamic team Jim has built. I look forward to supporting
AngioDynamics’ continued growth and its focus on improving patient
care,” commented Ms. Licitra.
Ms. Licitra served as Corporate Vice President for Worldwide
Government Affairs & Policy at Johnson & Johnson, a medical
device, pharmaceutical, and consumer packaged goods manufacturer
from January 2014 through August 2015. From December 2011 to
December 2013, Ms. Licitra served as the Worldwide Chairman, Global
Medical Solutions at Johnson & Johnson. From July 2002 to
November 2011, she served as the Company Group Chairman and
Worldwide Franchise Chairman at Ethicon Endo-Surgery, Inc., a
Johnson & Johnson medical device company. From January 2001 to
June 2002, she served as the President of Ethicon Endo-Surgery. Ms.
Licitra has been a member of the board of directors of Si-Bone,
Inc. (Nasdaq: SIBN) since August 2015. Ms. Licitra earned a
Bachelor of Science degree in Commerce from Rider College.
About AngioDynamics, Inc.
AngioDynamics, Inc. is a leading provider of innovative,
minimally invasive medical devices used by professional healthcare
providers for vascular access, peripheral vascular disease, and
oncology. AngioDynamics’ diverse product lines include
market-leading ablation systems vascular access products,
angiographic products and accessories, drainage products,
thrombolytic products and venous products. For more information,
visit www.angiodynamics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190731005955/en/
Investor Relations: AngioDynamics, Inc. Michael Greiner
518-795-1821 mgreiner@angiodynamics.com
Media: AngioDynamics, Inc. Saleem Cheeks 518-795-1174
scheeks@angiodynamics.com
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Apr 2024 to May 2024
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From May 2023 to May 2024